Related Experiment Video
Updated: Aug 4, 2026
08:18
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Lymphatic Mapping for Melanoma: Long-term Results of Regional Nodal Sampling With Radioguided Surgery
1Curaneous Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.
Cancer Control : Journal of the Moffitt Cancer Center
|April 14, 2000
Summary
Sentinel lymph node biopsy is crucial for staging malignant melanoma. Positive sentinel lymph nodes significantly predict survival outcomes in melanoma patients, guiding adjuvant therapy decisions.
Area of Science:
- Oncology
- Surgical Oncology
- Dermatology
Background:
- Lymphatic mapping and sentinel lymph node (SLN) biopsy are emerging techniques in malignant melanoma treatment.
- These procedures offer a more rational approach to adjuvant therapy for melanoma patients.
Purpose of the Study:
- To identify prognostic factors for overall and disease-free survival in melanoma patients undergoing SLN biopsy.
- To evaluate the effectiveness of SLN biopsy in staging primary cutaneous melanoma.
Main Methods:
- Prospective review of a database of melanoma patients who underwent lymphatic mapping and SLN biopsy.
- Statistical analysis to determine prognostic factors for survival.
Main Results:
- Five-year overall survival was 92.3% and disease-free survival was 79.0%.
- The number of positive SLNs was the strongest predictor of survival; patients with negative SLNs had 97.9% overall and 93.3% disease-free survival.
- Tumor ulceration and Clark level III or higher were also significant prognostic factors.
Conclusions:
- Lymphatic mapping and SLN biopsy are effective for staging primary cutaneous melanoma.
- Histologically positive SLNs are the most powerful indicator of patient survival in melanoma.
